linjc16/ctgov huggingface dataset:
Color Doppler Ultrasonography in Prediction of Arteriovenous Fistula Maturation in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
The transplant is the definitive treatment of renal insufficiency, in our days. While waiting for it, the arteriovenous fistula surgery is standard procedure.

Detailed Description
-----------------
Ultrasound is the main method of diagnostic imaging, because of its low cost, noninvasive without ionizing radiation associated or iodized contrast. Vascular procedures and their complications represent a major cause of morbidity hospitalization and cost for patients in hemodialysis . Many fistulas do not mature appropriately for being used in dialysis. So,The early recognition through the ultrasound examination of problems in the arteriovenous fistula maturation or possible complications that may compromise their viability, offers the opportunity of correction or appropriate treatment . Criteria for maturation after arteriovenous fistula creation: Vein diameter larger than 4 mm remote from the site of fistula. Vein located at a depth of <5 mm from skin surface.

Official Title
-----------------
Role of Color Doppler Ultrasonography in Prediction of Arteriovenous Fistula Maturation and Its Complications in Hemodialysis Patients

Conditions
-----------------
Arteriovenous Fistula

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) Patients Of Chronic Renal Failure With Newly Placed AVF. 2)Clinically Stable Patients For Assessment Of Maturation Of AVF. 3) Complaints Of Hand Pain Or Numbness Following Creation Of The Access. Exclusion Criteria: 1)Previously Failed AV Fistulas. 2)Deformed Or Scarred Upper Limb.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| maturation of arteriovenous fistula<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Role of color Doppler ultrasonography in prediction of arteriovenous fistula maturation and its complications in hemodialysis patients | Assess and monitor the maturation of the newly placed Arteriovenous fistulas, and to provide timely interventions for AV fistulas which are failing to mature | one month |
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia

Study Overview
=================
Brief Summary
-----------------
This is a research study of adults with hemophilia that have limitations in elbow joint motion that is the result of bleeding into the joint. People with hemophilia who have bleeding into their elbow joint may have limitations in elbow joint movement and pain in the joint. This research is being done to determine the effect a strength training program has on the amount of movement people with hemophilia and elbow joint disease have.

Official Title
-----------------
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia

Conditions
-----------------
Hemophilia, Elbow Joint Contracture

Intervention / Treatment
-----------------
* Other: Strength training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of the Oregon health and Science University Hemophilia treatment Center greater or equal to 18 years old Loss of elbow range of motion that is greater than or equal to 5 degrees Exclusion Criteria: Present inhibitor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Strength training<br> | Other: Strength training<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Elbow range of motion | measurement of change of range of motion over time frame | measurements to be taken at 4 and 8 weeks after entering study |
T1D, Metabolic Syndrome and Insulin Resistance

Study Overview
=================
Brief Summary
-----------------
Patients with type 1 diabetes (T1D) and metabolic syndrome (MS) require high doses of insulin to achieve a glycemic control, due to insulin resistance (IR). The investigators identified the presence of metabolic syndrome and insulin resistance in patients with T1D in a population of southeast Mexico. The sampled population was recruited from the Diabetes Clinic of the Regional Hospital of High Specialty Dr. Gustavo A. Rovirosa Pérez; from August 2021 to February 2022, graduated physicians interviewed patients previously diagnosed with T1D. This study included patients older than 18 years and at least six months after being diagnosed with T1D. The interviewers excluded patients who did not attend regular consultations and those who did not agree to participate or to give a blood sample. A diabetologist evaluated and diagnosed all patients based on the World Health Organization (WHO) criteria. Fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols were determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics. The reasearch team determined glycated hemoglobin concentrations by an enzymatic immunoassay method.

Official Title
-----------------
Clinical Characteristics in Adults With Type 1 Diabetes, Metabolic Syndrome and Insulin Resistance

Conditions
-----------------
Insulin Resistance, Type 1 Diabetes, Metabolic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least six months after being diagnosed with T1D Exclusion Criteria: Did not attend regular consultations Did not agree to participate or to give a blood sample

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycated hemoglobin | Concentrations by an enzymatic immunoassay method | March 2022 | 
| Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols | Determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics | March 2022 |
Antioxidant Effect of Aged Garlic Extract

Study Overview
=================
Brief Summary
-----------------
This is a randomized, double-blind, placebo controlled, crossover study to determine the antioxidant effect of aged garlic extract. This study will also compare the oxidative status in heavy smokers with that in non-smokers.

Official Title
-----------------
A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Antioxidant Effect of Aged Garlic Extract in Heavy Smokers

Conditions
-----------------
Heavy Smoker or Non-smoker

Intervention / Treatment
-----------------
* Dietary Supplement: Placebo
* Dietary Supplement: Aged garlic extract


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Smoking (at least 20 cigarettes per day) or non-smoking (more than 20 years) Exclusion Criteria: Under medication for chronic disease Garlic allergy Engaging in vigorous exercise Taking drugs or functional food that may possess antioxidant property Participation in any clinical trial within 90 days of the commencement of the trial Renal or hepatic dysfunction Heart disease

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Smoker subjects take 6 capsules once a day for 4 weeks. | Dietary Supplement: Placebo<br> <br> |
| Experimental: Aged garlic extract<br>Smoker subjects take 1.5 g of aged garlic extract in 6 capsules once a day for 4 weeks. | Dietary Supplement: Aged garlic extract<br> <br> |
| No Intervention: Non-smoker<br>Oxidative status in non-smoker | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary 8-hydroxydeoxyguanosine (8-OHdG) |  | Every 4 weeks (Overall 12 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| High sensitive CRP |  | Every 4 weeks (Overall 12 weeks) | 
| Blood pressure |  | Every 4 weeks (Overall 12 weeks) | 
| Indices of the second derivative of photoplethysmogram (SDPTG) |  | Every 4 weeks (Overall 12 weeks) |
Retrobulbar Block Versus Ketamine Infusion for Post-enucleation Analgesia

Study Overview
=================
Brief Summary
-----------------
This study compares the efficacy and safety of two techniques, retrobulbar block versus intra-operative ketamine infusion, for control of post-operative pain occurring in patients undergoing ocular enucleation or evisceration performed under general anesthesia.

Official Title
-----------------
Retrobulbar Block Versus Ketamine Infusion as Adjuvants to General Anesthesia for Post-operative Pain Control After Enucleation

Conditions
-----------------
Enucleated; Eye, Evisceration; Operation Wound, Pain, Postoperative

Intervention / Treatment
-----------------
* Procedure: Retrobulbar block
* Procedure: Ketamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ocular enucleation candidate patients Ocular evisceration candidate patients Exclusion Criteria: Any condition contra-indicating general or local anesthesia Allergy to any of the drugs used during the procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Retrobulbar group<br>Retrobulbar block | Procedure: Retrobulbar block<br>* Patients will receive a single retrobulbar injection with 3-4ml of an equal mixture of Lidocaine 2% & Bupivacaine 0.5% + Hyaluronidase (10 IU/ml), after induction of general anesthesia.<br>* Other names: Local analgesia;|
| Active Comparator: Ketamine group<br>Intravenous analgesia | Procedure: Ketamine<br>* Patients will receive a 0.5 mg/kg bolus followed by an infusion of 0.25 mg/kg/h of intravenous Ketamine, after induction of general anesthesia.<br>* Other names: IV analgesia;|
| No Intervention: Control group<br>General anesthesia alone | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to the first post-operative rescue analgesia. | Time (measured in minutes) elapsed till the patient requires to receive his first post-operative rescue analgesic dose. | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retrobulbar block, Ketamine, Ocular enucleation, Analgesia
COVID-19 and Chilblains

Study Overview
=================
Brief Summary
-----------------
Chilblains (inflammatory lesion of the feet or hands) have been reported with an unusual frequency during the confinement period, most commonly in children, teenagers and young adults. The aim of the ECCES study is to find out whether these manifestations of chilblains can be linked to the SARS-CoV-2 coronavirus. For this, an epidemiologic study will compare two types of family (or more precisely people who were confined together in March-April-May): case family in which at least one of the members had chilblains comparator family in which none of the members had chilblains Environment (home lockdown) of the two types of family will be analyzed. Each member of the family will be suggested doing a serological test.

Official Title
-----------------
Chilblains, COVID-19 and Lockdown: Epidemiologic Study

Conditions
-----------------
COVID-19, Chilblains

Intervention / Treatment
-----------------
* Diagnostic Test: Biological sample collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: case family at least one of the members with chilblains diagnosis of chilblains (anamnesis and pictures) written informed consent comparator family none of the members with chilblains one member matched on age (+/- 1 year) to a patient with chilblains written informed consent Exclusion Criteria: - Subject legally protected (under judicial protection, guardianship), persons deprived of liberty
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subjects with chilblains<br> | Diagnostic Test: Biological sample collection<br>* 10mL blood sample<br>|
| Active Comparator: Subjects without chilblains<br> | Diagnostic Test: Biological sample collection<br>* 10mL blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of viral exposure in case family compared to comparator family |  | Through study completion, an average of 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of seropositivity rates in subjects with chilblains and their age-matched controls |  | Through study completion, an average of 3 months | 
| Comparison of SARS-CoV-2 seropositivity rates among members of case (subject with chilblains) and control (subject without chilblains) outbreaks |  | Through study completion, an average of 3 months | 
| Antibody avidity and differentiated IgG and IgM assay by subject in the homes |  | Through study completion, an average of 3 months |
An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice

Study Overview
=================
Brief Summary
-----------------
The objective of this survey on this registered product is to confirm the efficacy, and safety profile of Lantus in every day medical practice. This program will also help to obtain information about the use of the insulin titration regimen and handling of the Lantus insulin analogue.

Official Title
-----------------
An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: INSULIN GLARGINE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All newly diagnosed diabetics and existing diabetics uncontrolled on other anti-diabetic therapy, where treatment with basal insulin is required to control hyperglycaemia, and who the treating investigator considers may benefit from the treatment with Lantus, could enter in this program. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: INSULIN GLARGINE<br>* The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycemic status (Fasting Blood Glucose, Fasting Plasma Glucose, and HbA1C as done in routine medical practice) |  | at least 3months |
Myometrial Biopsy for the Detection of Infection

Study Overview
=================
Brief Summary
-----------------
This study is designed to demonstrate that women in labor become infected without exhibiting any clinical signs or symptoms of infection.

Detailed Description
-----------------
The infection is a dynamic process probably beginning shortly after the onset of labor. This process continues and is enhanced during active uterine contractions, which result in bacteria from the vagina being drawn up into the uterine cavity. During labor, bacterial colonization of the amniotic fluid, the decidua, and even the fetus can occur, resulting in infection of the mother and the fetus.

Official Title
-----------------
Myometrial Biopsy for the Detection of Infection

Conditions
-----------------
Infection

Intervention / Treatment
-----------------
* Procedure: Biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be afebrile throughout labor. Amniotic fluid must be not purulent; presence of meconium is not an exclusion. Patients undergoing an elective cesarean section. Patients who have labored with intact or ruptured amniotic membranes. Exclusion Criteria: Patient with a temperature of ≥ 100.4o F. White blood cell count ≥ 24,000. Suspicion of chorioamnionitis. Suspicion of a urinary tract infection. Presence of diarrhea (defined > 4 liquid stools in a 24 hour period). Patient currently taking therapeutic antibiotics.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 48 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group 1<br>Patients who have labored and subsequently delivered by cesarean section | Procedure: Biopsy<br>* 1 centimeter x 1/2 centimeter piece cut from uterus<br>|
| Placebo Comparator: 2<br>Patients who electively select cesarean section | Procedure: Biopsy<br>* 1 centimeter x 1/2 centimeter piece cut from uterus<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative infection following rupture of amniotic membranes |  | Amount of time it takes to obtain culture result | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infection, postoperative, c-section
Study for Perioperative Neurocognitive Disorders After Deep Brain Stimulation Surgery for Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
Perioperative neurocognitive disorders(PND) is common to see in elderly patients. Although PND increases patient mortality as well as hospitalization time, apparent inflammatory factors, and related mechanisms are still unknown. Metabolites could reveal chemical fingerprints left behind by cellular processes, which in turn provide a new aspect to understand the biological process behind. we aim to found the metabolomics can aid the development of diagnostic markers of PND screening, early detection, and further, provide a basis for disease prevention and treatment.

Official Title
-----------------
Metabonomics Characteristics and Predictive Value for Perioperative Neurocognitive Disorders After Deep Brain Stimulation Surgery for Parkinson's Disease

Conditions
-----------------
Neurocognitive Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parkinson's patients undergoing elective deep brain stimulation Age ≥55 years ASA physical statusⅠ-Ⅲ Elementary school or above Exclusion Criteria: patients with ASA physical status>III patients with systemic immune diseases, hematological diseases (hematological tumors or leukemia), patients after transplantation, malignant tumors patients with metabolic diseases such as diabetes, ketoacidosis, hyperosmolar syndrome, long-term hypoglycemia,gout patients who refused to join the study and lost to follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PND group<br>patients occur neurocognitive disorders according to scores in this group | |
| NO PND group<br>patients do not occur neurocognitive disorders according to scores in this group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the level of metabolomics in patients' blood sample |  | baseline | 
| the level of metabolomics in patients' blood sample |  | 24 hours after operation | 
| the level of metabolomics in patients' blood sample |  | 72 hours after operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CAM-ICU score |  | baseline | 
| CAM-ICU score |  | 24 hours after operation | 
| CAM-ICU score |  | 72 hours after operation | 
| CAM-ICU score |  | 1 month after operation |